Journal
NATURE MEDICINE
Volume 6, Issue 1, Pages 41-48Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/71517
Keywords
-
Funding
- NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER
- NCI NIH HHS [CA52750, CA64239] Funding Source: Medline
Ask authors/readers for more resources
Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that limits vessel density in normal tissues and curtails tumor growth. Here, we show that the inhibition of angiogenesis in vitro and in vivo and the induction of apoptosis by thrombospondin-1 all required the sequential activation of CD36, p59(fyn), caspase-3 like proteases and p38 mitogen-activated protein kinases. We also detected increased endothelial cell apoptosis in situ at the margins of tumors in mice treated with thrombospondin-1. These results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available